A certain immune cell pattern is linked to longer survival in glioblastoma
Original title: CD163 Dominance Within Macrophages/Microglia Reflects a Favorable Prognosis in Patients With Glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Researchers studied tumor tissue from patients, but no treatment was tested.
The short version
In this study, people whose brain tumors had more of one kind of immune cell lived longer.
What was studied. Researchers looked at tumor tissue from 34 patients with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. They checked which immune cells, called microglia and macrophages, were most common in each tumor.
What they found. In 17.6% of cases, cells marked by CD163 were the main type. Those patients lived longer overall than patients whose tumors were mostly marked by IBA-1. The CD163 tumors also had more of a type of immune T cell, and fewer of certain blood vessels.
What this means, and what it doesn't
What it could mean: The mix of immune cells in a glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary may help explain why some people live longer than others. The researchers suggest these immune cells could be a target for future treatments.
What it doesn't mean: This is not a new treatment, and it is not a cure. It was a look back at tumor tissue from a small group of 34 people. No one was given a new drug here. Nothing about your care changes because of this study. It would take years of testing in people before this could lead to a treatment.
Source: PubMed, August 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.